The global biobanking market is expected to grow at a CAGR of 4.67% by 2032: Visiongain Reports Ltd

Visiongain Reports Ltd

Visiongain Reports Ltd

Visiongain has published a new report titled Biobanks 2022-2032. It includes biobank profiles and forecasts, market segments by type (autonomous, partnership) market segment by application, (regenerative medicine, life science research, clinical research) market segment by sample type, (blood products, human tissues, nucleic acids, cell lines). , Biological Fluids, Other Samples) Market Segment by Product and Service, (Equipment, Consumables, Services, Software) as well as COVID-19 Impact Analysis and Recovery Pattern Analysis (“V” shaped, “W” shaped, “U” shaped ”, shaped “L”), profiles of leading companies, region and country.

The global biobanking market was valued at US$56,955 million in 2021 and is expected to grow at a CAGR of 4.67% during the forecast period 2022-2032.

Growing opportunities for IT companies in the biobanking market

Biobanks work hard to allocate funding to IT companies as they are suitable for all biobank activities, from subject recruitment to publishing research results. The most important investment objectives include sample management as well as an accessible channel for organizations and individuals. An area of ​​growing interest is the use of common standards to provide access to clinical and experimental databases. If the ontology is properly standardized, this allows a thorough explanation of the examples. For example, the ongoing and resource-intensive standardization of disease coding and specimen classification. Standardization will become a major bottleneck for biobanks if it is not completed on time. Scientific concern about interoperability among biobanks is growing around the world.

Download form:

How has COVID-19 had a significant negative impact on the biobanking market?

Globally, the coronavirus 2019 (COVID-19) pandemic is significantly affecting the social, political, economic and healthcare systems of many countries around the world. There are many concurrent clinical concerns during a pandemic, from the urgent need to understand the biology of the disease to the need for optimal treatment of patients and prevention of future cases. Research infrastructures, especially biobanks, have put themselves at the forefront of the many distinct responses to the novel coronavirus. There have been reports of initiatives to compile population-level databases of COVID-19 patients, asymptomatic carriers, and members of the general public in the European Union (EU), Taiwan and elsewhere. An attempt to assemble clinically meaningful clusters also occurs in low resource situations where some infrastructure has been available and sustainable over time. In many cases, this effort is linked to a more open management structure for sample and data sharing.

How will this report benefit you?

The 558-page Visiongain Report provides 357 tables and 309 charts/graphs. Our new study is suitable for anyone who needs in-depth business analyzes of the global biobanking market, along with a detailed analysis of the segments in the market. Our new study will help you assess the overall global and regional market for biobanks. Get the financial analysis of the total market and different sectors including type, process, upstream and downstream, company size and get a higher market share. We believe there are strong opportunities in this fast-growing biobank market. Learn how to use current and upcoming opportunities in this market to reap revenue benefits in the near future. Moreover, the report will help you to improve your strategic decision-making process, allowing you to devise strategies for growth, enhance analysis of other market players, and maximize company productivity.

What are the current market drivers?

The rapidly evolving field of biobanking provides extensive sources of human biological material and related data

It appears that the main focus of biobanks is to learn about diseases and devise new treatments. In addition, although the goal of biobank research is to shed new light on the genetic underpinnings of human disease, another major goal is to provide a more mechanistic and adaptive therapeutic approach. With the rapid growth of biobanks, it is now possible to collect huge repositories of non-human biological material, including plants, animals, microorganisms, and more. The expansion of several biobanks, reporting and tracking is expected to revolutionize research, enabling personalized medicine and other benefits.

Increased focus on genetic testing and precision medicine

Conventional treatments often do not work today because they do not take into account the unique features and genetic makeup of a person. The search for a more effective and accurate treatment throughout history led to the creation of the scientific field known as “personalized medicine”. Personalized medicine has been recognized by future generations of diagnosis and treatment as a result of important technical advances in this field. Although it has received a lot of attention recently, significant obstacles still stand in the way of its application in clinical practice. The borders have recently emerged due to the COVID-19 pandemic. Precise and personalized medicine is transforming medical diagnosis and paving the way for a comprehensive, patient-centered diagnosis.

Download form:

Where are the market opportunities?

Advances in biomedical research and personalized treatment require human biosamples

The development of personalized medicine and the discovery of biomarkers are based on vital human samples. Biobanks collect, store, and distribute cells, blood, various vital fluids, and remaining tissue samples from patients for scientific study. Until recently, the market was very diverse, with biobanks catering to a particular market and not usually maintaining a comprehensive set of empirical information for each sample. It needs an overhaul, fortunately many new and exciting companies are starting to offer it. For the successful use of biosamples, associated data, and downstream research, as well as the biotechnology and pharmaceutical industries, biobanks are essential resources. The best biobanking technology is highly dependent on individuals and their interests. By sharing information, using cutting edge technology solutions, and adhering to some of the latest standards, biobanks can reach their full potential.

Increasing focus on cellular therapies

Patients can now receive treatment for a variety of diseases that were previously incurable due to the development in the cell and gene therapy industry. As a result, drug companies are spending a lot of money on research and development to develop new treatments, and many gene and cell therapy drugs are now in the early stages of development. Along with significant investment in research and development, the industry is expected to experience strong commercial growth. Emerging economies around the world provide a wide range of business opportunities for stakeholders.

Competitive scene
The major players operating in the biobanking market are AMS Biotechnology (Europe) Ltd. , ASKION GmbH, Avantor, Inc. , Azenta, Inc. (Azenta), Bay Biosciences LLC, Bioivt & Elevating Science, Boca Biolistics, CTI Biotech, Cureline Inc., Feralis SA, Geneticist Inc., Hamilton Bonaduz AG, Isenet Biobanking, Merck & Co., Inc., ProteoGenex Inc., Qiagen NV, Stemcell Holdings, Inc., STEMCELL Technologies Inc., Thermo Fisher Scientific Inc., US Biolab Corp. Inc.. The major players operating in this market have adopted various strategies including mergers and acquisitions, investment in research and development, collaborations, partnerships, regional business expansion and new product launch.

Recent Developments

  • On May 5, 2022, Avantor, Inc. About its plans to combine the existing distribution center with new manufacturing operations in Singapore to create a new manufacturing and distribution center.

  • On April 19, 2022, Applied Cells Inc. and STEMCELL Technologies Canada Inc. for their partnership to develop a new, high-performance cell separation solution that combines the MARS® platform from Applied Cells with the STEMCELL EasySep TM immune cell separation suite. Through this collaboration, researchers around the world will be able to more effectively and automatically separate high-quality cells from a variety of sample types, including whole blood, bone marrow, apheresis products and separated tissues.

Avoid getting lost by staying informed – order our report now.

To find more Visiongain research reports on the pharmaceutical sector, click on the following links:

Do you have any custom requirements we can help you with? Any need for a specific country, geographic region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help:

About Visiongain

Visiongain is one of the fastest growing and most innovative independent market information providers, and the company publishes hundreds of them Market Research Reports which it adds to its extensive portfolio every year. These reports provide in-depth analysis across 18 industries around the world. The reports, covering a 10-year forecast, are hundreds of pages long, with in-depth market analysis and valuable competitive intelligence data. Visiongain operates across a range of vertical markets with many synergies. These markets include the automotive, aviation, chemical, internet, defense, energy, food and beverage, materials and packaging, pharmaceutical and utility sectors. Our customized and combined market research reports provide a bespoke piece of market information tailored to your specific business needs.

Dave Visavadia
Public Relations at Visiongain Reports Limited
Tel: +44 0207336 6100

Leave a Comment